|
"peng c y"的相关文件
显示项目 191-215 / 360 (共15页)
<< < 3 4 5 6 7 8 9 10 11 12 > >>
每页显示[10|25|50]项目
| 臺大學術典藏 |
2021-05-06T01:25:13Z |
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
|
Liu C.-H.; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; Liu C.-J.; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; Fang Y.-J.; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; CHIEN-CHING HUNG; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.?Y.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-29T07:24:26Z |
Multimode VCSEL Enables Multi-Data-Format Encoding up to 124 Gbit/s
|
Lo, W.-C.; Wu, W.-L.; Peng, C.-Y.; Wang, H.-Y.; Tsai, C.-T.; Su, B.; Wu, C.-H.; Lin, G.-R.; GONG-RU LIN |
| 臺大學術典藏 |
2021-03-29T07:24:26Z |
Multimode VCSEL Enables 42-GBaud PAM-4 and 35-GBaud 16-QAM OFDM for 100-m OM5 MMF Data Link
|
Huang, C.-Y.; Wang, H.-Y.; Peng, C.-Y.; Tsai, C.-T.; Wu, C.-H.; Lin, G.-R.; GONG-RU LIN |
| 臺大學術典藏 |
2021-03-09T01:47:44Z |
Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion
|
Yang H.-C.; Chen C.-L.; Shen Y.-C.; Peng C.-Y.; Liu C.-J.; Tseng T.-C.; TUNG-HUNG SU; Chuang W.-L.; Yu M.-L.; Dai C.-Y.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:47:43Z |
Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir
|
Wang C.-C.; Tseng K.-C.; Peng C.-Y.; Hsieh T.-Y.; Lin C.-L.; TUNG-HUNG SU; Tseng T.-C.; Hsu C.-S.; Lin H.H.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:47:38Z |
HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
|
Peng C.-Y.; Hsieh T.-C.; Hsieh T.-Y.; Tseng K.-C.; Lin C.-L.; TUNG-HUNG SU; Tseng T.-C.; Lin H.H.; Wang C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:47:33Z |
Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan
|
Wang C.-C.; Lin C.-L.; Hsieh T.-Y.; Tseng K.-C.; Peng C.-Y.; TUNG-HUNG SU; Yang S.-S.; Hsu Y.-C.; Chen T.-M.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:47:32Z |
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
|
TUNG-HUNG SU; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; Chen C.-L.; Kao J.-H.; the C-TEAM study group; the Taiwan Liver Diseases Consortium |
| 臺大學術典藏 |
2021-03-09T01:43:16Z |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; TUNG-HUNG SU; Liu C.-J.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:14Z |
Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis
|
TUNG-HUNG SU; Peng C.-Y.; Tseng T.-C.; Yang H.-C.; Liu C.-J.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:14Z |
Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy
|
Yang H.-I.; Yeh M.-L.; Wong G.L.; Peng C.-Y.; Chen C.-H.; Trinh H.N.; Cheung K.-S.; Xie Q.; TUNG-HUNG SU; Kozuka R.; Lee D.-H.; Ogawa E.; Zhao C.; Ning H.-B.; Huang R.; Li J.; Zhang J.Q.; Ide T.; Xing H.; Iwane S.; Takahashi H.; Wong C.; Wong C.; Lin C.-H.; Hoang J.; Le A.; Henry L.; Toyoda H.; Ueno Y.; Gane E.J.; Eguchi Y.; Kurosaki M.; Wu C.; Liu C.; Shang J.; Furusyo N.; Enomoto M.; Kao J.-H.; Yuen M.-F.; Yu M.-L.; Nguyen M.H. |
| 臺大學術典藏 |
2021-03-09T01:43:13Z |
Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy
|
Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; TUNG-HUNG SU; Wang C.-C.; Liu C.-J.; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:12Z |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment
|
Liu C.-H.; Yang S.-S.; Peng C.-Y.; Lin W.-T.; Liu C.-J.; TUNG-HUNG SU; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:09Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; TUNG-HUNG SU; Liu C.-J.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-02-02T02:48:04Z |
Rather than interleukin-27, interleukin-6 expresses positive correlation with liver severity in naïve hepatitis B infection patients
|
Kao J.-T.; Lai H.-C.; Tsai S.-M.; Lin P.-C.; Chuang P.-H.; Yu C.-J.; Cheng K.-S.; Su W.-P.; PING-NING HSU; Peng C.-Y.; Wu Y.-Y. |
| 臺大學術典藏 |
2021-01-14T03:08:53Z |
General and abdominal adiposity and risk of death in HBV versus non-HBV carriers: A 10-year population-based cohort study
|
Lin W.-Y.; Peng C.-Y.; Lin C.-C.; Davidson L.E.; Pi-Sunyer F.X.; Sung P.-K.; KUO-CHIN HUANG |
| 國立成功大學 |
2021 |
Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines
|
Teng, W.;Chang, T.-T.;Yang, H.-I.;Peng, C.-Y.;Su, C.-W.;Su, T.-H.;Hu, T.-H.;Yu, M.-L.;Yang, H.-C.;Wu, J.-C. |
| 國立成功大學 |
2021 |
Herbal and dietary supplement-induced liver injury in Taiwan: comparison with conventional drug-induced liver injury
|
Huang, Y.-S.;Chang, T.-T.;Peng, C.-Y.;Lo, G.-H.;Hsu, C.-W.;Hu, C.-T.;Huang, Y.-H. |
| 國立成功大學 |
2021 |
Chaos-based secure communications in biomedical information application
|
Liao, T.-L.;Chen, H.-C.;Peng, C.-Y.;Hou, Y.-Y. |
| 國立成功大學 |
2021 |
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
|
Huang, C.-F.;Kuo, H.-T.;Chang, T.-S.;Lo, C.-C.;Hung, C.-H.;Huang, C.-W.;Chong, L.-W.;Cheng, P.-N.;Yeh, M.-L.;Peng, C.-Y.;Cheng, Cheng C.-Y.;Huang, J.-F.;Bair, M.-J.;Lin, C.-L.;Yang, C.-C.;Wang, S.-J.;Hsieh, T.-Y.;Lee, T.-H.;Lee, P.-L.;Wu, Wu W.-C.;Lin, C.-L.;Su, W.-W.;Yang, S.-S.;Wang, C.-C.;Hu, J.-T.;Mo, L.-R.;Chen, Chen C.-T.;Huang, Y.-H.;Chang, Chang C.-C.;Huang, C.-S.;Chen, G.-Y.;Kao, C.-N.;Tai, C.-M.;Liu, C.-J.;Lee, M.-H.;Tsai, P.-C.;Dai, C.-Y.;Kao, J.-H.;Lin, H.-C.;Chuang, W.-L.;Chen, Chen C.-Y.;Tseng, K.-C.;Yu, M.-L. |
| 國立成功大學 |
2021 |
Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)
|
Yeh, M.-L.;Hung, C.-H.;Tseng, K.-C.;Lai, H.-C.;Chen, Chen C.-Y.;Kuo, H.-T.;Wang, J.-H.;Chen, J.-J.;Lee, P.-L.;Chien, R.-N.;Yang, C.-C.;Lo, G.-H.;Tai, C.-M.;Lin, C.-W.;Kao, J.-H.;Liu, C.-H.;Yan, S.-L.;Bair, M.-J.;Lin, C.-Y.;Su, W.-W.;Chu, Chu C.-H.;Chen, Chen C.-J.;Tung, S.-Y.;Lo, C.-C.;Cheng, P.-N.;Chiu, Y.-C.;Wang, C.-C.;Cheng, J.-S.;Tsai, W.-L.;Lin, H.-C.;Huang, Y.-H.;Huang, C.-F.;Huang, J.-F.;Dai, C.-Y.;Chuang, W.-L.;Tsai, P.-C.;Peng, C.-Y.;Liu, C.-J.;Yu, M.-L. |
| 國立成功大學 |
2021 |
Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan
|
Hsieh, M.-H.;Bair, M.-J.;Tsai, P.-C.;Tseng, K.-C.;Lo, C.-C.;Chen, Chen C.-Y.;Kuo, H.-T.;Hung, C.-H.;Lai, H.-C.;Peng, C.-Y.;Wang, J.-H.;Chen, J.-J.;Lee, P.-L.;Chien, R.-N.;Yang, C.-C.;Lo, G.-H.;Kao, J.-H.;Liu, C.-J.;Liu, C.-H.;Yan, S.-L.;Lin, C.-Y.;Su, W.-W.;Chu, Chu C.-H.;Chen, Chen C.-J.;Tung, S.-Y.;Tai, C.-M.;Lin, C.-W.;Cheng, P.-N.;Chiu, Y.-C.;Wang, C.-C.;Cheng, J.-S.;Tsai, W.-L.;Lin, H.-C.;Huang, Y.-H.;Yeh, M.-L.;Huang, C.-F.;Huang, J.-F.;Dai, C.-Y.;Yu, M.-L.;Chuang, W.-L.;investigators, T-COACH |
| 國立成功大學 |
2021 |
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan
|
Chen, Chen C.-Y.;Huang, C.-F.;Cheng, P.-N.;Tseng, K.-C.;Lo, C.-C.;Kuo, H.-T.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Chen, Chen C.-H.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Chen, Chen C.-T.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Mo, L.-R.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Hsiung, C.-K.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Liu, C.-J.;Dai, C.-Y.;Kao, J.-H.;Chuang, W.-L.;Lin, H.-C.;Yu, M.-L. |
| 國立成功大學 |
2021 |
Drug-induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan
|
Huang, Y.-S.;Wu, C.-Y.;Chang, T.-T.;Peng, C.-Y.;Lo, G.-H.;Hsu, C.-W.;Hu, C.-T.;Huang, Y.-H. |
| 國立成功大學 |
2021 |
Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan
|
Cheng, P.-N.;Chen, Chen C.-Y.;Yu, M.-L.;Lin, C.-C.;Lin, C.-Y.;Peng, C.-Y.;Tseng, K.-C.;Lo, C.-C.;Tseng, I.-H.;Liu, C.-J. |
显示项目 191-215 / 360 (共15页)
<< < 3 4 5 6 7 8 9 10 11 12 > >>
每页显示[10|25|50]项目
|
